# A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period

Source: https://onco.cc/trials/nct06524375/  
OnCo record `nct06524375` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Venetoclax in chronic lymphocytic leukaemia, run by Genentech, Inc., active and no longer recruiting.

## Summary

A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period is a phase 2 interventional study registered as NCT06524375 by Genentech, Inc., with 118 participants enrolled, started 2024-08-09 and due to reach its primary completion in 2026-10-31. Interventions recorded: Venetoclax and cBTKi Monotherapy.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06524375
- Phase: 2
- Setting: Phase II, Open-label, Prospective Single-arm, Multi-center Clinical Trial to Evaluate if Adding Venetoclax to Patients on Covalent BTKi For 1L CLL Can Achieve Deep Durable Remissions (by UMRD 10^-4) to Allow Off-treatment Period
- Sponsor: Genentech, Inc.
- Enrolled: 118

## Sources

- ClinicalTrials.gov NCT06524375: https://clinicaltrials.gov/study/NCT06524375

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/)
- drugs: [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/)

---
JSON: https://onco.cc/api/v1/entities/nct06524375.json